111 related articles for article (PubMed ID: 8087328)
1. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group.
Spector SL; Smith LJ; Glass M
Am J Respir Crit Care Med; 1994 Sep; 150(3):618-23. PubMed ID: 8087328
[TBL] [Abstract][Full Text] [Related]
2. Two first-line therapies in the treatment of mild asthma: use of peak flow variability as a predictor of effectiveness.
Nathan RA; Minkwitz MC; Bonuccelli CM
Ann Allergy Asthma Immunol; 1999 May; 82(5):497-503. PubMed ID: 10353583
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219.
Smith LJ; Glass M; Minkwitz MC
Clin Pharmacol Ther; 1993 Oct; 54(4):430-6. PubMed ID: 8222486
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma.
Kemp JP; Minkwitz MC; Bonuccelli CM; Warren MS
Chest; 1999 Feb; 115(2):336-42. PubMed ID: 10027429
[TBL] [Abstract][Full Text] [Related]
5. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
Murphy K; Noonan M; Silkoff PE; Uryniak T
Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
Medley H; Orozco S; Allen A
Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
[TBL] [Abstract][Full Text] [Related]
7. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis.
Donnelly AL; Glass M; Minkwitz MC; Casale TB
Am J Respir Crit Care Med; 1995 Jun; 151(6):1734-9. PubMed ID: 7767514
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219.
Smith LJ; Geller S; Ebright L; Glass M; Thyrum PT
Am Rev Respir Dis; 1990 Apr; 141(4 Pt 1):988-92. PubMed ID: 2158260
[TBL] [Abstract][Full Text] [Related]
9. Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction.
O'Shaughnessy KM; Taylor IK; O'Connor B; O'Connell F; Thomson H; Dollery CT
Am Rev Respir Dis; 1993 Jun; 147(6 Pt 1):1431-5. PubMed ID: 8389105
[TBL] [Abstract][Full Text] [Related]
10. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction.
Nathan RA; Bernstein JA; Bielory L; Bonuccelli CM; Calhoun WJ; Galant SP; Hanby LA; Kemp JP; Kylstra JW; Nayak AS; O'Connor JP; Schwartz HJ; Southern DL; Spector SL; Williams PV
J Allergy Clin Immunol; 1998 Dec; 102(6 Pt 1):935-42. PubMed ID: 9847434
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses.
Tashkin DP; Nathan RA; Howland WC; Minkwitz MC; Simonson SG; Bonuccelli CM
J Allergy Clin Immunol; 1999 Feb; 103(2 Pt 1):246-54. PubMed ID: 9949315
[TBL] [Abstract][Full Text] [Related]
12. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
[TBL] [Abstract][Full Text] [Related]
13. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
FitzGerald JM; Boulet LP; Follows RM
Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
[TBL] [Abstract][Full Text] [Related]
14. Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids.
Crompton GK; Ayres JG; Basran G; Schiraldi G; Brusasco V; Eivindson A; Jamieson AH; Olsson H
Am J Respir Crit Care Med; 1999 Mar; 159(3):824-8. PubMed ID: 10051257
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children.
Pearlman DS; Lampl KL; Dowling PJ; Miller CJ; Bonuccelli CM
Clin Ther; 2000 Jun; 22(6):732-47. PubMed ID: 10929920
[TBL] [Abstract][Full Text] [Related]
16. Salmeterol versus theophylline in the treatment of asthma.
Pollard SJ; Spector SL; Yancey SW; Cox FM; Emmett A
Ann Allergy Asthma Immunol; 1997 May; 78(5):457-64. PubMed ID: 9164358
[TBL] [Abstract][Full Text] [Related]
17. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group.
Fish JE; Kemp JP; Lockey RF; Glass M; Hanby LA; Bonuccelli CM
Clin Ther; 1997; 19(4):675-90. PubMed ID: 9377612
[TBL] [Abstract][Full Text] [Related]
18. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma.
Hansel TT; Benezet O; Kafé H; Ponitz HH; Cheung D; Engelstätter R; Barnes PJ
Clin Ther; 2006 Jun; 28(6):906-20. PubMed ID: 16860173
[TBL] [Abstract][Full Text] [Related]
19. A controlled trial of twice daily triamcinolone oral inhaler in patients with mild-to-moderate asthma.
Ramsdell JW; Fish L; Graft D; Higgins N; Kavuru M; Pleskow W; Banerji D
Ann Allergy Asthma Immunol; 1998 May; 80(5):385-90. PubMed ID: 9609607
[TBL] [Abstract][Full Text] [Related]
20. The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma.
Makker HK; Lau LC; Thomson HW; Binks SM; Holgate ST
Am Rev Respir Dis; 1993 Jun; 147(6 Pt 1):1413-8. PubMed ID: 8389103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
